WebJan 3, 2024 · Throughout 2024, Mainz Biomed operated in a position of financial strength, having successfully executed a USD 25.8 million public follow-on offering in January, which consisted of 1,725,000 ordinary shares priced at USD 15.00 per share. During the year, to keep pace with product development and commercial growth, the Company made it a … WebApr 10, 2024 · ColoAlert Revenue Increases 130% Year over Year. Year End Cash Balance of $17.1 Million. BERKELEY, Calif. and MAINZ, Germany, April 10, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ ...
Mainz Biomed - MYNZ Stock Forecast, Price & News - MarketBeat
WebMar 15, 2024 · About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex ... WebFeb 21, 2024 · Mainz Biomed is commercializing ColoAlert across Europe and in select international markets through a differentiated business model of partnering with third-party laboratories for test kit ... how is value created in the gaming industry
Mainz Biomed Launches Number of Educational Events in
WebMar 15, 2024 · Mainz Biomed undertakes no obligation to publicly. update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future ... WebOct 28, 2024 · About. Mainz Biomed B.V. ( NASDAQ: MYNZ) is a molecular genetics cancer diagnostic company incorporated in 2024. Mainz Biomed was formed to acquire … Web21 hours ago · The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mainz Biomed B.V. with a $18.00 average price target, which is a 208.85% upside from current levels. how is value added tax calculated